|
1
|
Korkmaz T, Seber S and Basaran G: Review
of the current role of targeted therapies as maintenance therapies
in first and second line treatment of epithelial ovarian cancer; In
the light of completed trials. Crit Rev Oncol Hematol. 98:180–188.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ebell MH, Culp MB and Radke TJ: A
systematic review of symptoms for the diagnosis of ovarian cancer.
Am J Prev Med. 50:384–394. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Raavé R, de Vries RB, Massuger LF, van
Kuppevelt TH and Daamen WF: Drug delivery systems for ovarian
cancer treatment: A systematic review and meta-analysis of animal
studies. PeerJ. 3:e14892015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Watts S, Prescott P, Mason J, McLeod N and
Lewith G: Depression and anxiety in ovarian cancer: A systematic
review and meta-analysis of prevalence rates. BMJ Open.
5:e0076182015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Davis LL and Carpenter JS: A systematic
review of nonpharmacologic interventions for treatment-related
symptoms in women with ovarian cancer. Clin J Oncol Nurs.
19:535–542. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Huo YR, Richards A, Liauw W and Morris DL:
Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive
surgery (CRS) in ovarian cancer: A systematic review and
meta-analysis. Eur J Surg Oncol. 41:1578–1589. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Garziera M, Montico M, Bidoli E, Scalone
S, Sorio R, Giorda G, Lucia E and Toffoli G: Prognostic role of
serum antibody immunity to p53 oncogenic protein in ovarian cancer:
A systematic review and a meta-analysis. PLoS One. 10:e01403512015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bacalbașa N and Bălescu I: Total pelvic
exenteration for pelvic recurrence after advanced epithelial
ovarian cancer-A case report and literature review. J Med Life.
8:263–265. 2015.PubMed/NCBI
|
|
9
|
Sarafraz-Yazdi E, Gorelick C, Wagreich AR,
Salame G, Angert M, Gartman CH, Gupta V, Bowne WB, Lee YC, Abulafia
O, et al: Ex vivo efficacy of anti-cancer drug PNC-27 in the
treatment of patient-derived epithelial ovarian cancer. Ann Clin
Lab Sci. 45:650–658. 2015.PubMed/NCBI
|
|
10
|
Lin JJ, Egorova N, Franco R, Prasad-Hayes
M and Bickell NA: Ovarian cancer treatment and survival trends
among women older than 65 years of age in the United States,
1995–2008. Obstet Gynecol. 127:81–89. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Duda K, Cholewa H, Łabuzek K,
Boratyn-Nowicka A and Okopień B: Novel strategies of ovarian cancer
treatment. Pol Merkur Lekarski. 39:337–342. 2015.(In Polish).
PubMed/NCBI
|
|
12
|
Kobayashi M, Chiba A, Izawa H, Yanagida E,
Okamoto M, Shimodaira S, Yonemitsu Y, Shibamoto Y, Suzuki N and
Nagaya M: DC-vaccine study group at the Japan Society of Innovative
Cell Therapy (J-SICT): The feasibility and clinical effects of
dendritic cell-based immunotherapy targeting synthesized peptides
for recurrent ovarian cancer. J Ovarian Res. 7:482014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sundar S, Neal RD and Kehoe S: Diagnosis
of ovarian cancer. BMJ. 351:h44432015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Barrett CL, DeBoever C, Jepsen K, Saenz
CC, Carson DA and Frazer KA: Systematic transcriptome analysis
reveals tumor-specific isoforms for ovarian cancer diagnosis and
therapy. Proc Natl Acad Sci USA. 112:E3050–E3057. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wands JR: Prevention of hepatocellular
carcinoma. N Engl J Med. 351:1567–1570. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bronte G, Cicero G, Sortino G, Pernice G,
Catarella MT, D'Alia P, Cusenza S, Lo Dico S, Bronte E, Sprini D,
et al: Immunotherapy for recurrent ovarian cancer: A further piece
of the puzzle or a striking strategy? Expert Opin Biol Ther.
14:103–114. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tse BW, Collins A, Oehler MK, Zippelius A
and Heinzelmann-Schwarz VA: Antibody-based immunotherapy for
ovarian cancer: Where are we at? Ann Oncol. 25:322–331. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fauci JM, Sabbatino F, Wang Y,
Londoño-Joshi AI, Straughn JM Jr, Landen CN, Ferrone S and
Buchsbaum DJ: Monoclonal antibody-based immunotherapy of ovarian
cancer: Targeting ovarian cancer cells with the B7-H3-specific mAb
376.96. Gynecol Oncol. 132:203–210. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lage A: Immunotherapy and complexity:
Overcoming barriers to control of advanced cancer. MEDICC Rev.
16:65–72. 2014.PubMed/NCBI
|
|
20
|
Massarelli E, Papadimitrakopoulou V, Welsh
J, Tang C and Tsao AS: Immunotherapy in lung cancer. Transl Lung
Cancer Res. 3:53–63. 2014.PubMed/NCBI
|
|
21
|
‘Immunotherapy of metastatic breast cancer
patients with vitamin D-binding protein-derived macrophage
activating factor (GcMAF)’ by Yamamoto N, Suyama H, Yamamoto N and
Ushijima N. Int J Cancer. 135:15092014.PubMed/NCBI
|
|
22
|
Matsuda G, Imadome K, Kawano F, Mochizuki
M, Ochiai N, Morio T, Shimizu N and Fujiwara S: Cellular
immunotherapy with ex vivo expanded cord blood T cells in a
humanized mouse model of EBV-associated lymphoproliferative
disease. Immunotherapy. 7:335–341. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pan QZ, Tang Y, Wang QJ, Li YQ, Zhang L,
Li XD, Zhao JJ, Weng DS, Liu Q, Huang LX, et al: Adjuvant cellular
immunotherapy in patients with resected primary non-small cell lung
cancer. Oncoimmunology. 4:e10380172015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee SJ, Kang WY, Yoon Y, Jin JY, Song HJ,
Her JH, Kang SM, Hwang YK, Kang KJ, Joo KM and Nam DH: Natural
killer (NK) cells inhibit systemic metastasis of glioblastoma cells
and have therapeutic effects against glioblastomas in the brain.
BMC Cancer. 15:10112015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Greaves MF and Brown G: Purification of
human T and B lymphocytes. J Immunol. 112:420–423. 1974.PubMed/NCBI
|
|
26
|
Zamarin D, Vigil A, Kelly K, García-Sastre
A and Fong Y: Genetically engineered Newcastle disease virus for
malignant melanoma therapy. Gene Ther. 16:796–804. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Latifi A, Luwor RB, Bilandzic M,
Nazaretian S, Stenvers K, Pyman J, Zhu H, Thompson EW, Quinn MA,
Findlay JK and Ahmed N: Isolation and characterization of tumor
cells from the ascites of ovarian cancer patients: Molecular
phenotype of chemoresistant ovarian tumors. PLoS One. 7:e468582012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nikolic B, Cooke DT, Zhao G and Sykes M:
Both gamma delta T cells and NK cells inhibit the engraftment of
xenogeneic rat bone marrow cells and the induction of xenograft
tolerance in mice. J Immunol. 166:1398–1404. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Angell TE, Lechner MG, Jang JK, LoPresti
JS and Epstein AL: MHC class I loss is a frequent mechanism of
immune escape in papillary thyroid cancer that is reversed by
interferon and selumetinib treatment in vitro. Clin Cancer Res.
20:6034–6044. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
De Felice F, Marchetti C, Palaia I, Musio
D, Muzii L, Tombolini V and Panici PB: Immunotherapy of ovarian
cancer: The role of checkpoint inhibitors. J Immunol Res.
2015:1918322015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schwab CL, English DP, Roque DM, Pasternak
M and Santin AD: Past, present and future targets for immunotherapy
in ovarian cancer. Immunotherapy. 6:1279–1293. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kersual N, Garambois V, Chardès T, Pouget
JP, Salhi I, Bascoul-Mollevi C, Bibeau F, Busson M, Vié H,
Clémenceau B, et al: The human Müllerian inhibiting substance type
II receptor as immunotherapy target for ovarian cancer. Validation
using the mAb 12G4. MAbs. 6:1314–1326. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Recchia F, Candeloro G, Rosselli M, Bratta
M, Pasta V, D'Orazi V, Fumagalli LA and Rea S: Adjuvant ovarian
suppression, high-dose chemotherapy and immunotherapy for
premenopausal patients with high-risk breast cancer. Anticancer
Res. 35:6847–6853. 2015.PubMed/NCBI
|
|
34
|
Krishnan V, Berek JS and Dorigo O:
Immunotherapy in ovarian cancer. Curr Probl Cancer. 41:48–63. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Malecki M, Putzer E, Quach C, Dodivenaka C
and Tombokan X: Novel paradigm for immunotherapy of ovarian cancer
by engaging prophylactic immunity against hepatitis B virus. Clin
Transl Med. 5:442016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Khalil HS, Langdon SP, Goltsov A, Soininen
T, Harrison DJ, Bown J and Deeni YY: A novel mechanism of action of
HER2 targeted immunotherapy is explained by inhibition of NRF2
function in ovarian cancer cells. Oncotarget. 7:75874–75901. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Saoji V, Lade NR, Gadegone R and Bhat A:
Immunotherapy using purified protein derivative in the treatment of
warts: An open uncontrolled trial. Indian J Dermatol Venereol
Leprol. 82:42–46. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dhami S, Nurmatov U, Halken S, Calderón
MA, Muraro A, Roberts G, Toit GD, Kleine-Tebbe J, Larenas-Linnemann
D, Lau S, et al: Allergen immunotherapy for the prevention of
allergic disease: Protocol for a systematic review. Pediatr Allergy
Immunol. 27:236–241. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pawelec G: Immunotherapy and
immunoselection-tumour escape as the final hurdle. FEBS Lett.
567:63–66. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chouaib S: Tumor escape from the immune
response: A major hurdle for successful immunotherapy of cancer?
Tunis Med. 83 Suppl 12:S7–S10. 2005.
|
|
41
|
Plate JM and Fidler MJ: Immunotherapy to
overcome lung tumor cell-induced escape from immunosurveillance.
Immunotherapy. 2:757–760. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bremers AJ, Andreola S, Leo E, Gallino F,
Rini F, Lombardo C, Belli F, Kuppen PJ, Parmiani G and Castelli C:
T cell responses in colorectal cancer patients: Evidence for class
II HLA-restricted recognition of shared tumor-associated antigens.
Int J Cancer. 88:956–961. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Malmberg KJ: Effective immunotherapy
against cancer: A question of overcoming immune suppression and
immune escape? Cancer Immunol Immunother. 53:879–892. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tjin EP, Krebbers G, Meijlink KJ, van de
Kasteele W, Rosenberg EH, Sanders J, Nederlof PM, van de Wiel BA,
Haanen JB, Melief CJ, et al: Immune-escape markers in relation to
clinical outcome of advanced melanoma patients following
immunotherapy. Cancer Immunol Res. 2:538–546. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sutoh M, Kasuya E, Yayou KI, Ohtani F and
Kobayashi Y: Intravenous tryptophan administration attenuates
cortisol secretion induced by intracerebroventricular injection of
noradrenaline. Anim Sci J. 87:266–270. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sun L, Guo H, Jiang R, Lu L, Liu T and He
X: Engineered cytotoxic T lymphocytes with AFP-specific TCR gene
for adoptive immunotherapy in hepatocellular carcinoma. Tumour
Biol. 37:799–806. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dong T: CD8+ cytotoxic T lymphocytes in
human influenza virus infection. Natl Sci Rev. 2:264–265. 2015.
View Article : Google Scholar : PubMed/NCBI
|
